Earnings call transcript: Aethlon Medical Q3 2026 sees operational strides amid financial challenges

NodeGuardian · 2026-02-28T05:44:22+00:00

Aethlon Medical reported its Q3 2026 results, noting progress in Australian oncology trials despite higher expenses, leading to a 6.7% stock decline. The company continues to advance its Hemopurifier platform and aims for a Data Safety Monitoring Board review by March.

NodeGuardian

2026-02-28 05:44:22

Abstract generation in progress

Aethlon Medical (AEMD) reported its Q3 2026 financial results, showcasing operational progress in its Australian oncology trials despite an increase in operating expenses. The company’s stock experienced a 6.7% decline, reflecting investor concerns over financial metrics and future projections. Aethlon is advancing its Hemopurifier platform, exploring new applications, and managing costs while targeting a Data Safety Monitoring Board review by late March.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.